OncoTargets and therapy最新文献_第9页

Apolipoprotein E is a Potential Biomarker for Predicting Cancer Prognosis and is Correlated with Immune Infiltration 载脂蛋白 E 是预测癌症预后的潜在生物标记物，与免疫渗透相关

IF 4 4区医学

OncoTargets and therapy Pub Date : 2024-03-19 DOI: 10.2147/ott.s447319

Jinji Chen, Herong Zhu, Shaohua Chen, Hua Mi

{"title":"Apolipoprotein E is a Potential Biomarker for Predicting Cancer Prognosis and is Correlated with Immune Infiltration","authors":"Jinji Chen, Herong Zhu, Shaohua Chen, Hua Mi","doi":"10.2147/ott.s447319","DOIUrl":"https://doi.org/10.2147/ott.s447319","url":null,"abstract":"Background: Apolipoprotein E (APOE) is a polymorphic protein that plays a role in lipoprotein transformation and metabolism. It is involved in numerous physiological processes within the body and is closely associated with tumor growth and metastasis. However, the role of APOE in pan-cancer has yet to be evaluated. Therefore, studying the association between APOE and various cancer types is crucial for providing a basis for individualized treatment strategies and clinical prognosis assessment. Methods: We investigated the diagnostic and prognostic significance of APOE across 33 tumor types, as well as its correlation with tumor mutation burden (TMB) and microsatellite instability (MSI). Additionally, we employed the ESTIMATE and CIBERSORT algorithms to analyze the potential impact of APOE on the immune system. Furthermore, gene set enrichment analysis (GSEA) was conducted to explore its underlying physiological function. Results: Based on observations from a pan-cancer dataset, APOE expression was significantly different between cancer and normal tissues, and was simultaneously associated with survival outcomes in terms of cancer type, clinical annotation, TMB, MSI, and TICs abundance. In addition, the results also showed that expression of APOE may respond to a variety of cancer chemotherapy. Conclusion: The findings from this study strongly indicate a close association between APOE and tumor development. Moreover, APOE shows promise as a potential biomarker for predicting prognosis and response to immunotherapy in patients with pan-cancer. ","PeriodicalId":19534,"journal":{"name":"OncoTargets and therapy","volume":null,"pages":null},"PeriodicalIF":4.0,"publicationDate":"2024-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140169140","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Taking the Next Step in Double Refractory Disease: Current and Future Treatment Strategies for Chronic Lymphocytic Leukemia 双重难治性疾病的下一步：慢性淋巴细胞白血病当前和未来的治疗策略

IF 4 4区医学

OncoTargets and therapy Pub Date : 2024-03-08 DOI: 10.2147/ott.s443924

Manabu Hayama, John C Riches

{"title":"Taking the Next Step in Double Refractory Disease: Current and Future Treatment Strategies for Chronic Lymphocytic Leukemia","authors":"Manabu Hayama, John C Riches","doi":"10.2147/ott.s443924","DOIUrl":"https://doi.org/10.2147/ott.s443924","url":null,"abstract":"Abstract: Chronic lymphocytic leukemia (CLL) is a monoclonal B-cell lymphoproliferative disease with a high annual incidence in Western countries. As B-cell receptor (BCR) signaling and intrinsic apoptotic resistance play critical roles in the development and survival of CLL cells, therapeutic approaches targeting these pathways have been extensively investigated to tackle this incurable disease. Over the last decade, several Phase 3 trials have confirmed the superior efficacy of covalent Bruton tyrosine kinase inhibitors (cBTKis) and venetoclax, a selective B-cell lymphoma 2 (BCL2) inhibitor, over chemoimmunotherapy. This has been demonstrated in both the treatment-naïve and relapsed/refractory (RR) settings and includes patients with high-risk molecular features. However, these drugs are not curative, with patients continuing to relapse after treatment with both cBTKis and BCL2is, and the optimal treatment strategy for these patients has not been defined. Several novel agents with distinct mechanisms have recently been developed for CLL which have demonstrated efficacy in patients who have previously received cBTKis and BCL2i. In particular, novel BCR-signaling targeting agents have shown promising efficacy in early-phase clinical trials for RR-CLL. Furthermore, cancer immunotherapies such as bispecific antibodies and chimeric antigen receptor T-cells have also shown anti-tumor activity in patients with heavily pretreated RR-CLL. Personalised approaches with these novel agents and combination strategies based on the understanding of resistance mechanisms have the potential to overcome the clinical challenge of what to do next for a patient who has already had a cBTKi and venetoclax. Keywords: CLL, BTK inhibitor, BCL2 inhibitor, bispecific antibody, CAR-T cell therapy ","PeriodicalId":19534,"journal":{"name":"OncoTargets and therapy","volume":null,"pages":null},"PeriodicalIF":4.0,"publicationDate":"2024-03-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140073442","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

TSC22D2 Regulates ACOT8 to Delay the Malignant Progression of Colorectal Cancer TSC22D2 调控 ACOT8 以延缓结直肠癌的恶性进展

IF 4 4区医学

OncoTargets and therapy Pub Date : 2024-03-05 DOI: 10.2147/ott.s449244

Nana Zhou, Chaoqin Guo, Jingyang Du, Xu Zhang, Qiuran Xu, Xiaoliang Zheng, Linglan Tu

{"title":"TSC22D2 Regulates ACOT8 to Delay the Malignant Progression of Colorectal Cancer","authors":"Nana Zhou, Chaoqin Guo, Jingyang Du, Xu Zhang, Qiuran Xu, Xiaoliang Zheng, Linglan Tu","doi":"10.2147/ott.s449244","DOIUrl":"https://doi.org/10.2147/ott.s449244","url":null,"abstract":"Purpose: Colorectal cancer (CRC) is one of the cancers with high incidence and mortality rates worldwide. In China, there are approximately 400,000 new CRC cases each year, seriously endangering people’s life and health. Transforming growth factor β-stimulated clone 22 domain family, member 2 (TSC22D2) is widely expression in cancers, but the role of TSC22D2 in CRC are still unknown. Methods: Real‑time quantitative PCR (qRT-PCR) and Western blot were applied to determine the TSC22D2 levels. CCK-8, colony formation and transwell assays were used to determine the proliferation and metastasis abilities of CRC cells in vitro. In vivo metastatic potential was assessed using a subcutaneously injected mouse model and. Western-blot and immunoprecipitation experiments were used to study the mechanism of TSC22D2‑mediated metastasis. Results: We found TSC22D2 was deregulated in CRC tissues and cells and implied poor prognosis. Overexpression TSC22D2 significantly promoted CRC cells proliferation and tumorigenicity both in vitro and vivo, whereas knockdown TSC22D2 resulted in the opposite effects. Importantly using a co-immunoprecipitation (co-IP) assay combined with mass spectrometry analysis to identify TSC22D2-interacting acyl-coenzyme A thioesterases 8 (ACOT8), TSC22D2 maintained stability of ACOT8. Overexpression of TCC22D2 in CRC cells can promote the expression of ACOT8 and inhibit the proliferation and metastasis of CRC cells through EMT mechanism, highlighting the possibility of TSC22D2 as a potential target in CRC development. Conclusion: In summary, the present study revealed the inhibitory effect of TSC22D2 on the proliferation of colorectal cancer cells, suggesting that TSC22D2 may be an important tumor suppressor and a potential therapeutic target during colorectal carcinogenesis. Keywords: colorectal cancer, TSC22D2, ACOT8, EMT ","PeriodicalId":19534,"journal":{"name":"OncoTargets and therapy","volume":null,"pages":null},"PeriodicalIF":4.0,"publicationDate":"2024-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140026361","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Treatment of Abdominal Desmoplastic Small Round Cell Tumor Induces Acute Myeloid Leukemia-M5: A Case Report and Literature Review 治疗腹部去势小圆形细胞瘤诱发急性髓性白血病-M5：病例报告和文献综述

IF 4 4区医学

OncoTargets and therapy Pub Date : 2024-02-27 DOI: 10.2147/ott.s434286

Lan Liu, Meizuo Zhong, Xuan Zhou, Fanhua Kang, Yong Long, Junfeng Li

{"title":"Treatment of Abdominal Desmoplastic Small Round Cell Tumor Induces Acute Myeloid Leukemia-M5: A Case Report and Literature Review","authors":"Lan Liu, Meizuo Zhong, Xuan Zhou, Fanhua Kang, Yong Long, Junfeng Li","doi":"10.2147/ott.s434286","DOIUrl":"https://doi.org/10.2147/ott.s434286","url":null,"abstract":"Abstract: Desmoplastic small round cell tumor (DSRCT) is a rare and highly aggressive malignancy. Most patients are diagnosed at a late stage with poor prognosis. The treatment usually includes combined intensive chemotherapy, cytoreductive surgery, radiotherapy, and targeted therapy. Due to the low incidence rate and dismal survival, there is currently a lack of case reports on DSRCT with concurrent leukemia. We report a case of a young patient who achieved disease stabilization for 14 months after receiving 6 cycles of chemotherapy and whole abdominal radiation therapy (WART), followed by consolidation treatment with anlotinib. However, the treatment was terminated due to the development of Acute Myeloid Leukemia-M5 (AML-M5). Multimodal therapy may provide a survival benefit for rare tumors that lack standard treatment. However, intensive chemotherapy and extensive radiotherapy carry a risk of inducing secondary malignancies. This is the first reported case of concurrent DSRCT and AML-M5 with short intervals between onset. Keywords: desmoplastic small round cell tumor, whole abdominal radiation therapy, anlotinib, therapy-related acute myeloid leukemia ","PeriodicalId":19534,"journal":{"name":"OncoTargets and therapy","volume":null,"pages":null},"PeriodicalIF":4.0,"publicationDate":"2024-02-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139977309","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

SIRT6 Overexpression Induces Apoptosis of Nasopharyngeal Carcinoma by Inhibiting NF-κB Signaling [Retraction] SIRT6 过表达可通过抑制 NF-κB 信号诱导鼻咽癌凋亡 [撤回论文］

IF 4 4区医学

OncoTargets and therapy Pub Date : 2024-02-24 DOI: 10.2147/ott.s465407

Lei Ouyang, Liang Yi, Jingkun Li, Shijiang Yi, Shisheng Li, Peng Liu, Xinming Yang

引用次数: 0

Coronin 3 Promotes the Development of Oncogenic Properties in Glioma Through the Wnt/β-Catenin Signaling Pathway [Retraction] Coronin 3通过Wnt/β-Catenin信号通路促进胶质瘤致癌特性的形成 [撤回]

IF 4 4区医学

OncoTargets and therapy Pub Date : 2024-02-23 DOI: 10.2147/ott.s465180

Min Wang, Qi Li, Shengyuan Yu, Zexiang Zhang, Peng Qiu, Yubao Zhang, Wei Yang, Guangming Xu, Tongjiang Xu

引用次数: 0

LncRNA HCP5 Promotes Cell Invasion and Migration by Sponging miR-29b-3p in Human Bladder Cancer [Retraction] LncRNA HCP5 在人类膀胱癌中通过疏导 miR-29b-3p 促进细胞侵袭和迁移 [撤稿］

IF 4 4区医学

OncoTargets and therapy Pub Date : 2024-02-23 DOI: 10.2147/ott.s465403

Cheng Zhao, Yangle Li, Xiheng Hu, Ruizhe Wang, Wei He, Long Wang, Lin Qi, Shiyu Tong

引用次数: 0

Applications of Yttrium-90 (90Y) in Hepatocellular Carcinoma 钇-90（90Y）在肝细胞癌中的应用

IF 4 4区医学

OncoTargets and therapy Pub Date : 2024-02-23 DOI: 10.2147/ott.s445898

ZhongHao Jiang, Fan Yang, WanXiang Wang

引用次数: 0

The lncRNA LINC01194/miR-486-5p Axis Facilitates Malignancy in Non-Small Cell Lung Cancer via Regulating CDK4 [Retraction] lncRNA LINC01194/miR-486-5p轴通过调控CDK4促进非小细胞肺癌的恶性发展 [撤稿］

IF 4 4区医学

OncoTargets and therapy Pub Date : 2024-02-23 DOI: 10.2147/ott.s465182

Zhiwei Xing, Zhihua Zhang, Yanjun Gao, Xun Zhang, Xianglong Kong, Jianwu Zhang, Hongzhong Bai

引用次数: 0

Prognostic Factors and Construction of Nomogram Prediction Model of Lung Cancer Patients Using Clinical and Blood Laboratory Parameters 利用临床和血液实验室参数预测肺癌患者的预后因素并构建提名图预测模型

IF 4 4区医学

OncoTargets and therapy Pub Date : 2024-02-21 DOI: 10.2147/ott.s444396

Yamin Zhang, Wei Wan, Rui Shen, Bohao Zhang, Li Wang, Hongyi Zhang, Xiaoyue Ren, Jie Cui, Jinpeng Liu

{"title":"Prognostic Factors and Construction of Nomogram Prediction Model of Lung Cancer Patients Using Clinical and Blood Laboratory Parameters","authors":"Yamin Zhang, Wei Wan, Rui Shen, Bohao Zhang, Li Wang, Hongyi Zhang, Xiaoyue Ren, Jie Cui, Jinpeng Liu","doi":"10.2147/ott.s444396","DOIUrl":"https://doi.org/10.2147/ott.s444396","url":null,"abstract":"Objective: This work aimed to explore the prognostic risk factors of lung cancer (LC) patients and establish a line chart prediction model. Methods: A total of 322 LC patients were taken as the study subjects. They were randomly divided into a training set (n = 202) and a validation set (n = 120). Basic information and laboratory indicators were collected, and the progression-free survival (PFS) and overall survival (OS) were followed up. Single-factor and cyclooxygenase (COX) multivariate analyses were performed on the training set to construct a Nomogram prediction model, which was validated with 120 patients in the validation set, and Harrell’s consistency was analyzed. Results: Single-factor analysis revealed significant differences in PFS (P< 0.05) between genders, body mass index (BMI), carcinoembryonic antigen (CEA), cancer antigen 125 (CA125), squamous cell carcinoma antigen (SCCA), treatment methods, treatment response evaluation, smoking status, presence of pericardial effusion, and programmed death ligand 1 (PD-L1) at 0 and 1– 50%. Significant differences in OS (P< 0.05) were observed for age, tumor location, treatment methods, White blood cells (WBC), uric acid (UA), CA125, pro-gastrin-releasing peptide (ProGRP), SCCA, cytokeratin fragment 21 (CYFRA21), and smoking status. COX analysis identified male gender, progressive disease (PD) as treatment response, and SCCA > 1.6 as risk factors for LC PFS. The consistency indices of the line chart models for predicting PFS and OS were 0.782 and 0.772, respectively. Conclusion: Male gender, treatment response of PD, and SCCA > 1.6 are independent risk factors affecting the survival of LC patients. The PFS line chart model demonstrates good concordance. Keywords: laboratory parameters, LC, nomogram prediction model, KM analysis, cox multivariate analysis ","PeriodicalId":19534,"journal":{"name":"OncoTargets and therapy","volume":null,"pages":null},"PeriodicalIF":4.0,"publicationDate":"2024-02-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139917867","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0